Opus Genetics, Inc.

NASDAQ:IRD

Biotechnology

Healthcare
$3.92 -0.12%

-$0.01 today

Market cap
$326.13M
Beta
0.55
P/E (TTM)
-33.0
EPS (TTM)
-$0.12
52W Low $0.90High $5.81

Volume 0.75M

Average 0.81M

IRD Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Opus Genetics, Inc.NASDAQ: IRD

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $13K rose 0.0% year over year, behind the +130.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +136.6% a year.

Context

  • Depreciation & amortization amounted to 0.4% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +130.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$13K+0.0% QoQ
Last fiscal yearDec 2025
$53K+430.0% YoY
LTMMar 2026
$53K+130.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year+430.0%——
3-year CAGR+136.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
53K USD
Year-over-year change
+430.0%
4-year CAGR
+90.8%

Depreciation & Amortization vs competitors

How IRD compares with its peers on the latest reported figures

  • IRD's LTM Mar 2026 depreciation & amortization of $53K is the 9th largest of the 10 companies compared; the peer median is $2.99M.
  • Its year-over-year change of +130.4% is the 2nd highest of 9, against a peer median of -13.1%.
  • Depreciation & amortization amounts to 0.4% of revenue for IRD, versus a peer median of 40.1%.
IRD Competitors Peer median
Depreciation & Amortization for IRD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$8.78M +4.6%—47.7%
AGENAgenus Inc.LTM Mar 2026$7.38M -44.0%+24.3%6.0%
SEERSeer, Inc.LTM Mar 2026$4.89M -22.2%+22.5%32.5%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$3.84M -23.0%-14.6%334.6%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.99M -3.9%-18.4%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$880K +391.6%——
CGTXCognition Therapeutics, Inc.LTM Mar 2026$251K -0.8%-1.0%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$80.68K —-42.4%—
IRDOpus Genetics, Inc.LTM Mar 2026$53K +130.4%+136.6%0.4%
TILInstil Bio, Inc.LTM Mar 2026$48K -98.5%-55.3%—
Peer median (excluding IRD) $2.99M-13.1%-14.6%40.1%

Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(56.69M)17.89M(9.99M)(57.53M)(49.59M)
Depreciation & Amortization4K4K6K10K53K
Deferred Income Tax00000
Stock-Based Compensation1.91M1.81M3.51M3.36M3.4M
Change in Working Capital181K(5.56M)4.08M3.09M(2.15M)
Accounts Receivables0(4.85M)2.52M(3.44M)2.61M
Inventory00000
Accounts Payables381K(515K)1.08M220K7K
Other Working Capital(200K)(190K)477K6.31M(4.77M)
Other Non-Cash Items35.22M170K1.28M25.49M13.04M
Operating Cash Flow(19.37M)14.31M(1.11M)(25.58M)(35.25M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(100K)001.21M0
Investing Cash Flow(100K)001.21M0
Debt Repayment538K(538K)001M
Common Stock Issued28.49M4.43M9.23M4.5M49.18M
Common Stock Repurchased000(79K)(152K)
Dividends Paid00000
Other Financing Activities(1.42M)(104K)(248K)(232K)0
Financing Cash Flow27.61M3.79M8.98M4.19M50.02M
Effect of Forex Changes00000
Net Change in Cash8.14M18.1M7.87M(20.18M)14.77M
Free Cash Flow(19.37M)14.31M(1.11M)(25.58M)(35.25M)

Opus Genetics, Inc.

NASDAQ:IRD

Intrinsic Alpha fair value

Locked

Current Price

$3.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.